Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Trial Profile

Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Suramin sodium (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 10 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
    • 20 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top